Cooper Companies, Inc. (COO) KPIs and segments
Close on Nov 18, 2026Market cap $11.55BP/E 20.7Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Cooper Companies · năm tài chính kết thúc ngày 31 tháng 10
Nhìn nhanh KPI của Cooper Companies: 37 chỉ số vận hành, trong đó có CooperVision — Organic Revenue Growth (YoY), Toric & Multifocal Lenses và Sphere & Other Lenses, lấy từ 184 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của Cooper Companies kết thúc ngày 31 tháng 10 — Q4 FY26 = CQ3 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Coopervision Segment($M)2 | 717 | 724 | 695 | 710 | 718 | 670 | 646 | 676 | 676 | 636 | 622 | ||
Toric and multifocal($M) | 364 | 365 | 351 | 345 | 359 | 328 | 319 | 323 | 326 | 310 | 297 | ||
Sphere, other($M) | 353 | 359 | 344 | 365 | 360 | 341 | 327 | 353 | 349 | 326 | 324 | ||
CooperVision($M) | 717 | 724 | 695 | 710 | 718 | 670 | 646 | ||||||
Coopersurgical Segment($M)2 | 349 | 358 | 329 | 355 | 342 | 333 | 319 | 342 | 327 | 307 | 310 | ||
Office and surgical($M) | 208 | 214 | 202 | 215 | 205 | 206 | 199 | 203 | 198 | 183 | 191 | ||
Fertility($M) | 141 | 144 | 127 | 141 | 137 | 127 | 120 | 139 | 129 | 124 | 119 | ||
CooperSurgical($M) | 349 | 358 | 329 | 355 | 342 | 333 | 319 | ||||||
United States($M) | 520 | 548 | 514 | 526 | 516 | 515 | 496 | 505 | 511 | 479 | 470 | ||
Europe($M) | 358 | 342 | 326 | 331 | 343 | 292 | 288 | 306 | 297 | 277 | 277 | ||
Rest of world($M) | 189 | 192 | 184 | 201 | 195 | 181 | 195 | 187 | 185 | ||||
CooperVision($M) | 206 | 216 | 210 | 157 | 203 | 186 | 184 | ||||||
Coopervision Segment($M) | 203 | 186 | 184 | 173 | 160 | 155 | |||||||
CooperSurgical($M) | 41.1 | -225 | 26.8 | 3.70 | -4.20 | 23.7 | 20.2 | ||||||
Coopersurgical Segment($M) | -4.20 | 23.7 | 20.2 | 41.3 | 21.6 | 24 | |||||||
CooperVision($M) | 477 | 494 | 474 | 436 | 480 | 454 | 441 | ||||||
CooperSurgical($M) | 235 | 241 | 221 | 215 | 212 | 225 | 219 | ||||||
CooperSurgical($M) | -8.30 | -9.80 | -8 | -6.50 | -10.5 | -8.70 | -13.8 | ||||||
CooperVision($M) | -60.4 | -76.6 | -94.2 | -91.5 | -86.4 | -69.4 | -75.6 | ||||||
CooperVision($M) | 7,915 | 7,626 | 7,656 | 7,604 | 7,285 | ||||||||
Coopervision Segment($M) | 7,512 | 7,463 | 7,259 | 7,285 | 7,172 | 7,115 | 7,130 | ||||||
Coopersurgical Segment($M) | 4,671 | 4,764 | 4,778 | 4,832 | 4,717 | 4,692 | 4,663 | ||||||
CooperSurgical($M) | 4,543 | 4,616 | 4,585 | 4,619 | 4,832 | ||||||||
CooperVision — Organic Revenue Growth (YoY)(%)4 | 0.0% | 4.0% | 3.0% | 3.0% | 2.0% | 7.0% | 6.0% | 8.0% | 10.0% | 11.0% | 7.0% | ||
Constant Currency Revenue Growth (YoY)(%) | 0.0% | 4.0% | 3.0% | 3.0% | 2.0% | 7.0% | 6.0% | 8.0% | 9.0% | 10.0% | 6.0% | ||
Reported GAAP Revenue Growth (YoY)(%) | 0.0% | 8.0% | 8.0% | 5.0% | 6.0% | 5.0% | 4.0% | 9.0% | 7.0% | 8.0% | 7.0% | ||
Foreign Currency Impact on Growth(%) | 0.0% | -4.0% | -5.0% | -2.0% | -4.0% | 2.0% | 2.0% | -1.0% | 2.0% | 2.0% | |||
Acquisitions & Divestitures Impact on Growth(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | 1.0% | |||
Toric & Multifocal Lenses — Organic Revenue Growth (YoY)(%)3 | 2.0% | 7.0% | 6.0% | 5.0% | 6.0% | 7.0% | 10.0% | 9.0% | 12.0% | 12.0% | 12.0% | ||
Constant Currency Growth (YoY)(%) | 2.0% | 7.0% | 6.0% | 5.0% | 6.0% | 7.0% | 10.0% | 9.0% | 12.0% | 12.0% | 12.0% | ||
Reported Growth (YoY)(%) | 1.0% | 11.0% | 10.0% | 7.0% | 10.0% | 6.0% | 7.0% | 9.0% | 10.0% | 11.0% | 14.0% | ||
Foreign Currency Impact(%) | 1.0% | -4.0% | -4.0% | -2.0% | -4.0% | 1.0% | 3.0% | 0.0% | 2.0% | 1.0% | |||
Sphere & Other Lenses — Organic Revenue Growth (YoY)(%)3 | -1.0% | 1.0% | 1.0% | 2.0% | -1.0% | 6.0% | 3.0% | 7.0% | 8.0% | 9.0% | 3.0% | ||
Constant Currency Growth (YoY)(%) | -1.0% | 1.0% | 1.0% | 2.0% | -1.0% | 6.0% | 3.0% | 7.0% | 7.0% | 8.0% | 1.0% | ||
Reported Growth (YoY)(%) | -2.0% | 5.0% | 5.0% | 3.0% | 3.0% | 5.0% | 1.0% | 8.0% | 5.0% | 5.0% | 1.0% | ||
Foreign Currency Impact(%) | 1.0% | -4.0% | -4.0% | -1.0% | -4.0% | 1.0% | 2.0% | -1.0% | 2.0% | 3.0% | |||
MiSight 1 day (Pediatric Myopia Control) — Organic Revenue Growth (YoY)(%) | 20.0% | 24.0% | 23.0% | ||||||||||
CooperVision EMEA — Net Sales($M)4 | 309 | 290 | 282 | 277 | 292 | 249 | 247 | 257 | 257 | 237 | 238 | ||
EMEA Organic Growth (YoY)(%) | 5.0% | 6.0% | 4.0% | 3.0% | 6.0% | 6.0% | 6.0% | 11.0% | 7.0% | 14.0% | 10.0% | ||
EMEA Constant Currency Growth (YoY)(%) | 5.0% | 6.0% | 4.0% | 3.0% | 6.0% | 6.0% | 6.0% | 11.0% | 7.0% | 13.0% | 8.0% | ||
EMEA Reported Growth (YoY)(%) | 6.0% | 17.0% | 15.0% | 8.0% | 14.0% | 5.0% | 3.0% | 14.0% | 6.0% | 13.0% | 11.0% | ||
EMEA Foreign Currency Impact(%) | -1.0% | -11.0% | -11.0% | -5.0% | -8.0% | 1.0% | 3.0% | -3.0% | 1.0% | 0.0% | |||
CooperVision Americas — Net Sales($M)4 | 282 | 303 | 289 | 285 | 286 | 282 | 271 | 271 | 280 | 264 | 253 | ||
Americas Organic Growth (YoY)(%) | -2.0% | 7.0% | 6.0% | 5.0% | 3.0% | 8.0% | 8.0% | 6.0% | 13.0% | 10.0% | 6.0% | ||
Americas Constant Currency Growth (YoY)(%) | -2.0% | 7.0% | 6.0% | 5.0% | 3.0% | 8.0% | 8.0% | 6.0% | 13.0% | 8.0% | 4.0% | ||
Americas Reported Growth (YoY)(%) | -2.0% | 7.0% | 7.0% | 5.0% | 2.0% | 7.0% | 7.0% | 5.0% | 13.0% | 9.0% | 5.0% | ||
Americas Foreign Currency Impact(%) | 0.0% | 0.0% | -1.0% | 0.0% | 1.0% | 1.0% | 1.0% | 1.0% | 0.0% | -1.0% | |||
CooperVision Asia Pacific — Net Sales($M)4 | 126 | 131 | 124 | 147 | 140 | 139 | 129 | 149 | 139 | 135 | 131 | ||
Asia Pacific Organic Growth (YoY)(%) | -5.0% | -6.0% | -4.0% | 0.0% | -5.0% | 5.0% | 3.0% | 7.0% | 7.0% | 7.0% | 7.0% | ||
Asia Pacific Constant Currency Growth (YoY)(%) | -5.0% | -6.0% | -4.0% | 0.0% | -5.0% | 5.0% | 3.0% | 7.0% | 7.0% | 7.0% | 6.0% | ||
Asia Pacific Reported Growth (YoY)(%) | -10.0% | -6.0% | -4.0% | -1.0% | 1.0% | 3.0% | -2.0% | 7.0% | 0.0% | -1.0% | 4.0% | ||
Asia Pacific Foreign Currency Impact(%) | 5.0% | 0.0% | 0.0% | 1.0% | -6.0% | 2.0% | 5.0% | 0.0% | 7.0% | 8.0% | |||
CooperSurgical — Organic Revenue Growth (YoY)(%)4 | 3.0% | 6.0% | 2.0% | 4.0% | 2.0% | 7.0% | 2.0% | 5.0% | 5.0% | 4.0% | 8.0% | ||
Constant Currency Revenue Growth (YoY)(%) | 2.0% | 6.0% | 2.0% | 4.0% | 4.0% | 9.0% | 4.0% | 12.0% | 10.0% | 8.0% | 13.0% | ||
Reported GAAP Revenue Growth (YoY)(%) | 2.0% | 8.0% | 3.0% | 4.0% | 4.0% | 8.0% | 3.0% | 12.0% | 9.0% | 6.0% | 12.0% | ||
Foreign Currency Impact(%) | 0.0% | -2.0% | -1.0% | 0.0% | 0.0% | 1.0% | 1.0% | 0.0% | 1.0% | 2.0% | |||
Acquisitions & Divestitures Impact(%) | 1.0% | 0.0% | 0.0% | 0.0% | -2.0% | -2.0% | -2.0% | -7.0% | -5.0% | -4.0% | |||
Fertility Portfolio — Organic Revenue Growth (YoY)(%)4 | 5.0% | 10.0% | 3.0% | 1.0% | 3.0% | 2.0% | 1.0% | 13.0% | 10.0% | 4.0% | 11.0% | ||
Fertility Constant Currency Growth (YoY)(%) | 4.0% | 10.0% | 3.0% | 1.0% | 4.0% | 4.0% | 3.0% | 15.0% | 9.0% | 2.0% | 9.0% | ||
Fertility Reported Growth (YoY)(%) | 3.0% | 13.0% | 6.0% | 1.0% | 6.0% | 3.0% | 1.0% | 15.0% | 6.0% | -1.0% | 6.0% | ||
Fertility Foreign Currency Impact(%) | 1.0% | -3.0% | -3.0% | 0.0% | -2.0% | 1.0% | 2.0% | 0.0% | 3.0% | 3.0% | |||
Fertility Acquisitions & Divestitures Impact(%) | 1.0% | 0.0% | 0.0% | 0.0% | -1.0% | -2.0% | -2.0% | -2.0% | 1.0% | 2.0% | |||
Office & Surgical Portfolio — Organic Revenue Growth (YoY)(%)5 | 2.0% | 4.0% | 2.0% | 6.0% | 1.0% | 10.0% | 2.0% | 0.0% | 2.0% | 4.0% | 6.0% | ||
Specialty & OB/GYN Medical Devices Subsegment — Organic Growth (YoY)(%) | 4.0% | 6.0% | 6.0% | ||||||||||
Office & Surgical Constant Currency Growth (YoY)(%) | 2.0% | 4.0% | 1.0% | 6.0% | 3.0% | 13.0% | 4.0% | 11.0% | 11.0% | 12.0% | 16.0% | ||
Office & Surgical Reported Growth (YoY)(%) | 2.0% | 4.0% | 2.0% | 6.0% | 3.0% | 13.0% | 4.0% | 11.0% | 11.0% | 12.0% | 16.0% | ||
Office & Surgical Foreign Currency Impact(%) | 0.0% | 0.0% | -1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |||
Office & Surgical Acquisitions & Divestitures Impact(%) | 0.0% | 0.0% | 1.0% | 0.0% | -2.0% | -3.0% | -2.0% | -11.0% | -9.0% | -8.0% | |||
Non-Current Customer Contract Liabilities (Multi-Year Stem Cell Storage)($M)2 | 209 | 209 | 206 | 202 | 199 | 196 | 193 | 193 | 191 | 189 | 186 | ||
Current Customer Contract Liabilities (Deferred Revenue)($M) | 130 | 128 | 130 | 128 | 127 | 128 | 126 | 130 | 126 | 122 | 122 | ||
Revenue Recognized from Beginning-of-Year Contract Liability Balance($M) | 32 | 32.5 | 32 | 31.9 | 31.6 | 32.5 | 31.6 | 30 | 31 | 31 | |||
CooperVision — Research & Development Expense($M)8 | 22.3 | 22.1 | 22.4 | 24.3 | 25.6 | 22.5 | |||||||
CooperSurgical — Research & Development Expense($M) | 19.3 | 20.4 | 21.9 | 20.3 | 19.9 | 18.2 | |||||||
CooperVision — SG&A Expense($M) | 245 | 252 | 238 | 248 | 237 | 230 | |||||||
CooperSurgical — SG&A Expense($M) | 132 | 402 | 128 | 151 | 137 | 136 | |||||||
Corporate Unallocated SG&A Expense($M) | 24.6 | 21.6 | 24.2 | 22.7 | 25.3 | 22.1 | |||||||
CooperVision — Depreciation Expense($M) | 40.9 | 41.3 | 41.1 | 39 | 37.1 | 35.3 | |||||||
CooperSurgical — Depreciation Expense($M) | 6.70 | 6.50 | 6.50 | 6.70 | 5.90 | 6.10 | |||||||
CooperVision — Intangible Amortization Expense($M) | 4.20 | 4.20 | 4.10 | 5.10 | 5.10 | 4.80 | |||||||
CooperSurgical — Intangible Amortization Expense($M) | 42.8 | 43.5 | 43.8 | 44.9 | 44.7 | 44.8 | |||||||
Consolidated Organic Revenue Growth (YoY)(%)2 | 1.0% | 5.0% | 3.0% | 3.0% | 2.0% | 7.0% | 6.0% | 7.0% | 8.0% | 8.0% | 8.0% | ||
Consolidated Constant Currency Revenue Growth (YoY)(%) | 1.0% | 5.0% | 3.0% | 3.0% | 3.0% | 7.0% | 6.0% | 9.0% | 10.0% | 9.0% | 8.0% | ||
Consolidated Reported Revenue Growth (YoY)(%) | 1.0% | 8.0% | 6.0% | 5.0% | 6.0% | 6.0% | 4.0% | 10.0% | 8.0% | 7.0% | 9.0% | ||
Common Shares Repurchased(M)3 | 4.90 | 0.20 | 1.10 | 0.70 | 0.50 | 0 | 0 | 0 | 0 | 0 | |||
Remaining Share Repurchase Authorization($M) | 522 | 861 | 874 | 966 | 164 | 216 | 256 | 256 | 256 | 256 | |||
Average Price Paid per Repurchased Share($) | 69.16 | 75.84 | 82.04 | 71.97 | 75.60 | ||||||||
Treasury Stock Held at Period-End(M) | 27.8 | 23 | 22.8 | 21.7 | 18.8 | 18.1 | 17.6 | 17.6 | 17.6 | 17.7 | 17.7 | ||
Non-GAAP Diluted EPS($)10 | 1.15 | 1.21 | 1.10 | 1.15 | 1.10 | 0.96 | 0.92 | 1.04 | 0.96 | 0.85 | 0.85 | ||
Non-GAAP Net Income($M) | 222 | 237 | 217 | 228 | 220 | 194 | 184 | 209 | 192 | 170 | 171 | ||
Non-GAAP Operating Income($M) | 281 | 297 | 275 | 288 | 276 | 250 | 242 | 263 | 256 | 225 | 227 | ||
Non-GAAP Operating Margin(%) | 26.0% | 27.0% | 27.0% | 27.0% | 26.0% | 25.0% | 25.0% | 26.0% | 26.0% | 24.0% | 24.0% | ||
Non-GAAP Gross Profit($M) | 711 | 736 | 698 | 705 | 713 | 682 | 662 | 682 | 668 | 634 | 627 | ||
Non-GAAP Gross Margin(%) | 67.0% | 68.0% | 68.0% | 66.0% | 67.0% | 68.0% | 69.0% | 67.0% | 67.0% | 67.0% | 67.0% | ||
EU MDR & IVDR Medical Device Regulation Compliance Costs (Operating)($M) | 2.60 | 2.60 | 4.30 | 6.40 | 4.80 | 5.30 | 5.40 | 4 | 5.60 | 5 | 5.20 | ||
EU MDR & IVDR Compliance Costs in Cost of Goods Sold($M) | 0.60 | 0.70 | 0.70 | 1.90 | 0.70 | 0.70 | 0.60 | 0.40 | 1 | 0.70 | 1 | ||
Acquisition & Integration-Related Charges (Operating)($M) | -1.40 | 0 | 0 | 15.7 | 13.6 | 9.60 | 4.30 | 7.20 | 1.10 | 1.80 | 10.5 | ||
Business Optimization & Restructuring Charges (Operating)($M) | 1.10 | 1.10 | 1.90 | 48.2 | 2.70 | 0 | 0 | 2.90 | 4.40 | 4.20 | 6.80 | ||
Exit of Business & Product Line Rationalization Charges (Operating)($M) | 0 | 0 | 1.80 | 24.6 | 27.2 | 0 | 0 | 0 | 2.50 | 1.10 | 0.40 | ||
Full-Year Consolidated Organic Growth Guidance — Low(%)13 | 2.0% | 3.5% | 4.5% | 4.5% | 4.0% | 5.0% | 6.0% | 6.0% | 8.0% | 7.5% | 7.0% | ||
Full-Year Consolidated Organic Growth Guidance — High(%) | 3.0% | 4.5% | 5.5% | 5.5% | 4.5% | 6.0% | 8.0% | 8.0% | 8.5% | 8.5% | 8.0% | ||
Full-Year Consolidated Revenue Guidance — Low($M) | 4,229 | 4,285 | 4,306 | 4,299 | 4,076 | 4,107 | 4,080 | 4,080 | 3,892 | 3,863 | 3,847 | ||
Full-Year Consolidated Revenue Guidance — High($M) | 4,252 | 4,321 | 4,346 | 4,338 | 4,096 | 4,146 | 4,158 | 4,158 | 3,913 | 3,905 | 3,897 | ||
Full-Year CooperVision Organic Growth Guidance — Low(%) | 1.0% | 3.5% | 4.5% | 4.5% | 4.0% | 6.0% | 6.5% | 6.5% | 9.0% | 8.5% | 8.0% | ||
Full-Year CooperVision Organic Growth Guidance — High(%) | 2.0% | 4.5% | 5.5% | 5.5% | 5.0% | 7.0% | 8.5% | 8.5% | 9.5% | 9.5% | 9.0% | ||
Full-Year CooperVision Revenue Guidance — Low($M) | 2,828 | 2,883 | 2,906 | 2,900 | 2,734 | 2,759 | 2,733 | 2,733 | 2,606 | 2,591 | 2,573 | ||
Full-Year CooperVision Revenue Guidance — High($M) | 2,842 | 2,908 | 2,932 | 2,925 | 2,747 | 2,786 | 2,786 | 2,786 | 2,618 | 2,613 | 2,604 | ||
Full-Year CooperSurgical Organic Growth Guidance — Low(%) | 4.0% | 4.0% | 4.0% | 4.0% | 3.0% | 3.5% | 4.0% | 4.0% | 5.5% | 5.0% | 5.0% | ||
Full-Year CooperSurgical Organic Growth Guidance — High(%) | 5.0% | 5.0% | 5.0% | 5.0% | 3.5% | 4.5% | 6.0% | 6.0% | 6.5% | 7.0% | 7.0% | ||
Full-Year CooperSurgical Revenue Guidance — Low($M) | 1,401 | 1,402 | 1,400 | 1,399 | 1,343 | 1,347 | 1,347 | 1,347 | 1,286 | 1,272 | 1,274 | ||
Full-Year CooperSurgical Revenue Guidance — High($M) | 1,410 | 1,414 | 1,413 | 1,413 | 1,349 | 1,359 | 1,372 | 1,372 | 1,294 | 1,292 | 1,293 | ||
Full-Year Non-GAAP Diluted EPS Guidance — Low($) | 4.51 | 4.58 | 4.58 | 4.45 | 4.08 | 4.05 | 3.94 | 3.92 | 3.64 | 3.54 | 3.50 | ||
Full-Year Non-GAAP Diluted EPS Guidance — High($) | 4.55 | 4.66 | 4.66 | 4.60 | 4.12 | 4.11 | 4.02 | 4.02 | 3.67 | 3.60 | 3.58 | ||
Inventory — Finished Goods($M)3 | 705 | 695 | 672 | 633 | 662 | 660 | 628 | 596 | 545 | 540 | 520 | ||
Inventory — Raw Materials($M) | 184 | 181 | 180 | 193 | 199 | 202 | 195 | 188 | 215 | 213 | 209 | ||
Inventory — Work-in-Process($M) | 22 | 20.9 | 24.1 | 19.9 | 20 | 18.3 | 20.1 | 18.5 | 19.5 | 23.1 | 18.8 | ||
Allowance for Credit Losses on Trade Receivables($M) | 76.1 | 69.1 | 58.7 | 51.9 | 52.1 | 52.2 | 48.1 | 43.5 | 42.8 | 39.9 | 34.7 | ||
Gross PP&E — Machinery & Automated Contact Lens Molding Equipment1 | |||||||||||||
Depreciation of Property, Plant & Equipment($M) | 47.6 | 47.8 | 47.6 | 45.7 | 43 | 41.4 | |||||||
Finite-Lived Intangible Assets — Gross Carrying Amount($M)13 | 3,165 | 3,176 | 3,177 | 3,170 | 3,190 | 3,197 | 3,186 | 3,191 | 3,137 | 3,090 | 3,093 | ||
Finite-Lived Intangible Assets — Accumulated Amortization($M) | 1,721 | 1,683 | 1,636 | 1,585 | 1,555 | 1,504 | 1,448 | 1,401 | 1,352 | 1,302 | 1,254 | ||
Finite-Lived Intangible Assets — Net Carrying Amount($M) | 1,445 | 1,493 | 1,541 | 1,585 | 1,635 | 1,693 | 1,738 | 1,789 | 1,785 | 1,788 | 1,839 | ||
Gross Intangibles — Customer Relationships($M) | 1,138 | 1,142 | 1,143 | 1,138 | 1,137 | 1,136 | 1,126 | 1,131 | 1,123 | 1,123 | 1,126 | ||
Gross Intangibles — Composite Intangible Assets($M) | 1,102 | 1,102 | 1,102 | 1,102 | 1,102 | 1,102 | 1,102 | 1,102 | 1,102 | 1,062 | 1,062 | ||
Gross Intangibles — Patents & Technology($M) | 692 | 685 | 684 | 683 | 703 | 707 | 707 | 706 | 660 | 653 | 653 | ||
Gross Intangibles — Trademarks($M) | 199 | 203 | 203 | 203 | 203 | 205 | 203 | 204 | 204 | 204 | 205 | ||
Gross Intangibles — License, Distribution Rights & Other($M) | 33.7 | 44.6 | 44.5 | 44.5 | 44.7 | 47.9 | 47.9 | 47.9 | 48 | 47.7 | 47.8 | ||
Indefinite-Lived Intangible Assets (Excluding Goodwill)($M) | 1.10 | 1.10 | 1.10 | 1.10 | 1.10 | 1.10 | 1.90 | 1.80 | 1.90 | 9.30 | 9.30 | ||
Amortization of Intangible Assets($M) | 47 | 47.7 | 47.9 | 50 | 49.8 | 49.6 | 50.2 | 50.4 | 50.3 | 50.3 | |||
Estimated Intangible Amortization — Year 1 (Next Fiscal Year)($M) | 174 | 175 | 175 | 189 | 189 | 191 | 190 | 198 | 192 | 188 | 188 | ||
Estimated Intangible Amortization — Year 2($M) | 170 | 170 | 170 | 174 | 175 | 176 | 176 | 190 | 184 | 180 | 180 | ||
Estimated Intangible Amortization — Year 3($M) | 166 | 166 | 166 | 170 | 170 | 172 | 171 | 176 | 170 | 166 | 166 | ||
Estimated Intangible Amortization — Year 4($M) | 162 | 162 | 162 | 166 | 166 | 167 | 167 | 171 | 165 | 161 | 161 | ||
Committed Revolving & Term Credit Facility Capacity3 | |||||||||||||
Finance Lease Liabilities — Non-Current($M) | 1.60 | 1.80 | 1.70 | 1.80 | 1.90 | 2 | 2.10 | 2.40 | 2.80 | 3 | 3.30 | ||
Finance Lease Liabilities — Current($M) | 0.60 | 0.70 | 0.60 | 0.70 | 0.90 | 1 | 1 | 1.10 | 1 | 1 | 1 | ||
Current Employee-Related Compensation & Benefit Liabilities($M) | 175 | 166 | 210 | 211 | 181 | 157 | 190 | 175 | 157 | 145 | 179 | ||
FDA Premarket Approvals & Supplements (PMA — CooperVision & CooperSurgical)5 | 1 | 3 | 7 | 5 | 4 | 10 | 7 | 5 | 8 | 15 | 0 | 2 | |
FDA 510(k) Clearances (CooperVision, CooperSurgical & Subsidiaries) | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | |
FDA Medical Device Recall Events (CooperVision & CooperSurgical) | 4 | 0 | 0 | 0 | 3 | 5 | 1 | 6 | 7 | 0 | 2 | 3 | |
FDA Enforcement Reports (CooperVision & CooperSurgical) | 4 | 0 | 0 | 0 | 3 | 5 | 1 | 6 | 7 | 0 | 2 | 3 | |
U.S. MedTech Industry — Total FDA PMA Decisions | 568 | 616 | 641 | 434 | 613 | 597 | 564 | 607 | 569 | 575 | 486 | 582 | |
U.S. MedTech Industry — Total FDA 510(k) Clearances | 868 | 889 | 835 | 736 | 823 | 882 | 767 | 812 | 814 | 793 | 750 | 780 | |
FDA MAUDE Medical Device Reports — Cooper Total MDRs4 | 147 | 63 | 60 | 45 | 32 | 38 | 41 | 42 | 61 | 47 | 60 | 51 | |
FDA MAUDE MDRs — Device Malfunction | 99 | 35 | 17 | 16 | 3 | 9 | 14 | 21 | 13 | 12 | 22 | 8 | |
FDA MAUDE MDRs — Injury | 47 | 28 | 43 | 29 | 28 | 28 | 27 | 21 | 48 | 35 | 38 | 43 | |
FDA MAUDE MDRs — Death | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
U.S. MedTech Industry — Total FDA MAUDE MDRs | 1,137,930 | 963,665 | 824,539 | 784,473 | 760,623 | 743,346 | 650,998 | 704,375 | 705,389 | 660,962 | 598,054 | 575,423 | |
ClinicalTrials.gov — Sponsored Studies Started (CooperVision & CooperSurgical) | 1 | 3 | 1 | 2 | 1 | 1 | 2 | 4 | 3 | 3 | 4 | 6 | |
Consolidated Net Sales($M)8 | 1,066 | 1,082 | 1,024 | 1,065 | 1,060 | 1,002 | 965 | 1,018 | 1,003 | 943 | 932 | ||
Gross Profit($M) | 712 | 735 | 695 | 651 | 692 | 679 | 660 | 678 | 663 | 631 | 624 | ||
Research & Development Expense($M) | 41.6 | 42.5 | 44.3 | 41.4 | 44.6 | 45.5 | 40.7 | 37.7 | 39 | 38.9 | 39.5 | ||
Selling, General & Administrative Expense($M) | 401 | 676 | 390 | 419 | 422 | 399 | 388 | 391 | 381 | 380 | 381 | ||
Operating Income($M) | 222 | -31 | 213 | 140 | 176 | 185 | 182 | 198 | 193 | 162 | 153 | ||
Interest Expense($M) | 21.5 | 20.9 | 22.4 | 24.4 | 25.4 | 24.2 | 26 | 27 | 28.5 | 28.9 | 29.9 | ||
Net Income Attributable to Cooper Stockholders($M) | 433 | -77.9 | 131 | 84.6 | 98.3 | 87.7 | 104 | 118 | 105 | 88.9 | 81.2 | ||
GAAP Diluted EPS($) | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Weighted-Average Diluted Shares(M) | 193 | 195 | 197 | 200 | 201 | 201 | 201 | 201 | 200 | ||||
Operating Cash Flow($M)3 | 342 | 183 | 261 | 248 | 261 | 96.2 | 191 | 268 | 208 | 111 | 123 | ||
Capital Expenditures($M) | 68.7 | 86.4 | 102 | 98 | 96.9 | 78.1 | 89.4 | 140 | 89 | 74.1 | 118 | ||
Stock-Based Compensation($M) | 15.9 | 15.5 | 19.2 | 15.2 | 16.2 | 20.3 | 18.8 | 16.4 | 17.6 | 17.2 | 23.9 | ||
Cash Paid for Share Repurchases($M) | 339 | 15.5 | 92.5 | 197 | 52.7 | 40.6 | -0 | -0 | -0 | ||||
Total Assets($M)7 | 12,673 | 12,482 | 12,424 | 12,395 | 12,377 | 12,414 | 12,222 | 12,315 | 12,108 | 12,047 | 12,033 | ||
Cash & Cash Equivalents($M) | 155 | 139 | 125 | 111 | 125 | 116 | 101 | 108 | 110 | 112 | 135 | ||
Accounts Receivable, Net($M) | 789 | 809 | 807 | 829 | 792 | 781 | 716 | 717 | 739 | 689 | 651 | ||
Inventories, Net($M) | 912 | 896 | 876 | 846 | 881 | 880 | 843 | 803 | 779 | 775 | 748 | ||
Property, Plant & Equipment, Net($M) | 2,145 | 2,132 | 2,117 | 2,082 | 1,989 | 1,929 | 1,865 | 1,861 | 1,748 | 1,709 | 1,682 | ||
Goodwill($M) | 3,876 | 3,889 | 3,905 | 3,853 | 3,862 | 3,865 | 3,792 | 3,838 | 3,777 | 3,761 | 3,773 | ||
Other Intangible Assets, Net($M) | 1,446 | 1,494 | 1,542 | 1,586 | 1,636 | 1,694 | 1,739 | 1,791 | 1,787 | 1,797 | 1,848 | ||
Total Stockholders' Equity($M) | 8,328 | 8,239 | 8,364 | 8,239 | 8,353 | 8,288 | 8,127 | 8,083 | 7,925 | 7,804 | 7,695 | ||
15 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- The Cooper Companies, Inc. operates on a fiscal year ending October 31 (for example, FY2025 ended October 31, 2025; Q1 FY2026 ended January 31, 2026; Q2 FY2026 ended April 30, 2026; Q3 FY2026 ended July 31, 2026).
- Primary operational metrics focus on: (1) CooperVision organic and constant-currency revenue growth, pediatric myopia control (MiSight 1 day) organic growth, and CooperVision regional net sales across EMEA, Americas, and Asia Pacific; (2) CooperSurgical organic growth across Fertility and Office & Surgical (including Specialty/OB-GYN Medical Devices), prepaid multi-year newborn stem cell storage contract liabilities (Cord Blood Registry), and ASU 2023-07 segment R&D, SG&A, depreciation, and amortization; and (3) monthly and quarterly share repurchases, split-adjusted Non-GAAP execution, EU MDR/IVDR regulatory compliance costs, and quarterly full-year guidance.
- All growth rates, regional net sales, non-GAAP reconciliations, sustainability figures, and statutory UK subsidiary metrics are directly reported; no ratios, margins, sums, or growth rates are computed. The only derived cells are cumulative period splits from year-to-date cash flow and footnote tables (Q4 = full year − nine months; quarterly = year-to-date − prior year-to-date). Per-share metrics reflect the 4-for-1 stock split completed in February 2024.
Không hiện vì thiếu các kỳ gần đây (11)
- CooperVision — Organic Growth, Myopia Control & Regional Mix (Key #1) › MiSight 1 day (Pediatric Myopia Control) — Organic Revenue Growth (YoY) › MiSight 1 day Quarterly Revenue — excluded due to missing recent periods required for strict continuity
- CooperVision — Organic Growth, Myopia Control & Regional Mix (Key #1) › MiSight 1 day (Pediatric Myopia Control) — Organic Revenue Growth (YoY) › Daily Silicone Hydrogel Portfolio — Organic Growth (YoY) — excluded due to missing recent periods required for strict continuity
- Consolidated Organic Growth, Share Repurchases, Non-GAAP Execution & Guidance (Key #3) › Common Shares Repurchased › Monthly Average Price Paid per Repurchased Share — excluded due to missing recent periods required for strict continuity
- Manufacturing Capacity, Inventory Stages, Intangibles & Lease Commitments › Committed Revolving & Term Credit Facility Capacity › Current Litigation Settlement Reserve — excluded due to missing recent periods required for strict continuity
- Form 10-K Year-End Global Headcount ('more than 15,000' as of October 31, 2025) — excluded because disclosed as an open-ended lower bound in Form 10-K; exact point headcounts from the Corporate Sustainability Reports (15,496 in FY2025) are included instead
- Global Contact Lens Wearer Share ('roughly 1/3 of all wearers' / '#1 global contact lens company' in Q2 FY2026 earnings call) — excluded because disclosed qualitatively without a continuous numerical series
- Paragard IUD Quarterly Organic Revenue Growth (%) — excluded because Q2 and Q3 FY2026 earnings calls described performance qualitatively as 'flat' without an explicit numerical digit
- Workforce Gender & U.S. Racial/Ethnic Representation (%) — reported for 2021–2024 in prior Sustainability Reports but discontinued in the 2025 Corporate Sustainability Report
- Global Employee Engagement Rate (84% in 2023, 90% in 2024) — excluded because the global engagement survey was not conducted in 2025
- Scope 3 GHG Emissions (701,680 tCO2e in FY2025) — excluded because disclosed as a single-year figure in the 2025 Corporate Sustainability Report (<2 consecutive years)
- Long-Term Cumulative Free Cash Flow Objective ('exceeding $2.2 billion for fiscal years 2026 through 2028') — excluded because stated as a multi-year open-ended lower bound
Dữ liệu cập nhật 2026-11-18.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
CooperVision — Organic Growth, Myopia Control & Regional Mix (Key #1)
- CooperVision — Organic Revenue Growth (YoY) (%)36 kỳ
- Toric & Multifocal Lenses — Organic Revenue Growth (YoY) (%)11 kỳ
- Sphere & Other Lenses — Organic Revenue Growth (YoY) (%)11 kỳ
- MiSight 1 day (Pediatric Myopia Control) — Organic Revenue Growth (YoY) (%)3 kỳ
- CooperVision EMEA — Net Sales ($M)35 kỳ
- CooperVision Americas — Net Sales ($M)36 kỳ
- CooperVision Asia Pacific — Net Sales ($M)36 kỳ
CooperSurgical — Fertility, Stem Cell Storage & Segment Expense Structure (Key #2)
- CooperSurgical — Organic Revenue Growth (YoY) (%)36 kỳ
- Fertility Portfolio — Organic Revenue Growth (YoY) (%)35 kỳ
- Office & Surgical Portfolio — Organic Revenue Growth (YoY) (%)35 kỳ
- Non-Current Customer Contract Liabilities (Multi-Year Stem Cell Storage) ($M)17 kỳ
- CooperVision — Research & Development Expense ($M)6 kỳ
Consolidated Organic Growth, Share Repurchases, Non-GAAP Execution & Guidance (Key #3)
Manufacturing Capacity, Inventory Stages, Intangibles & Lease Commitments
- Inventory — Finished Goods ($M)36 kỳ
- Gross PP&E — Machinery & Automated Contact Lens Molding Equipment ($M)7 kỳ
- Principal Leased Facility Space — Juana Díaz, Puerto Rico (CVI Manufacturing & R&D, sq. ft.)4 kỳ
- Finite-Lived Intangible Assets — Gross Carrying Amount ($M)36 kỳ
- Committed Revolving & Term Credit Facility Capacity ($M)9 kỳ
Plastic Neutrality, Environmental Footprint, Safety, Workforce & Supply Chain
- Ocean-Bound Plastic Bottles Recovered via Plastic Bank Partnership (M)4 kỳ
- CooperVision (CVI) — Total Recordable Incident Rate (TRIR, per 100 FTEs) (×)3 kỳ
- Scope 1 + Scope 2 GHG Emissions — Market-Based (metric tons CO2e)5 kỳ
- SASB HC-MS-250a.1: Total FDA Recalls per $1M Revenue (×)4 kỳ
- Global Workforce Headcount5 kỳ
- Identified 3TG Smelters & Refiners in Supply Chain3 kỳ
CooperVision Manufacturing Ltd & CooperVision International Ltd — UK Statutory Disclosures
External Regulatory, Clinical & Industry Benchmarks (FDA, ClinicalTrials.gov, USAspending & BLS)
- FDA Premarket Approvals & Supplements (PMA — CooperVision & CooperSurgical)118 kỳ
- FDA MAUDE Medical Device Reports — Cooper Total MDRs118 kỳ
- ClinicalTrials.gov — Sponsored Studies Started (CooperVision & CooperSurgical)39 kỳ
- U.S. Federal Contract Obligations — CooperVision & CooperSurgical Total ($M)118 kỳ
- U.S. BLS Producer Price Index — Ophthalmic Goods Manufacturing (NAICS 339115 / SIC 3851) (×)118 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Cooper Companies
- The Cooper Companies Form 8-K Earnings Release (Exhibit 99.1), filed 2026-09-09 ↗
- The Cooper Companies Form 10-K, filed 2025-12-05 ↗
- The Cooper Companies Form 10-Q, filed 2026-09-09 ↗
- The Cooper Companies Corporate Sustainability / ESG Report (2025) ↗
- U.S. Food and Drug Administration — openFDA Medical Device Database ↗
- U.S. Food and Drug Administration — openFDA Medical Device Database ↗
- The Cooper Companies Form 10-Q, filed 2026-09-09 ↗
- The Cooper Companies Form 10-K, filed 2025-12-05 ↗
- The Cooper Companies Form 8-K Earnings Release (Exhibit 99.1), filed 2024-12-05 ↗
- The Cooper Companies Form 8-K Earnings Release (Exhibit 99.1), filed 2025-12-04 ↗
- UK Government Equalities Office — Statutory Gender Pay Gap Service (2025 Snapshot) ↗
- U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
See a number that looks wrong?